Tetratherix Limited 2026Tissue Spacing FranchiseSUCCESSFUL COMPLETION INDEPENDENTOPTIMATRIX PRECLINICAL EVALUATIONAnchored by ScienceASX Release16 September 2026ASX:TTXHIGHLIGHTSSuccessful completion of the first preclinical performance study for Optimatrix in cataract surgery with a...
Line of sight ophthalmic tissue spacing US revenue
Filed with ASX · · 4 pages · English
Release
Earlier from Tetratherix
- Tetratherix Ships First US Polymer, Revenue Begins
- Application for quotation of securities - TTX
- Results Presentation 2026
- Appendix 4E and Annual Report 2026
- Successful Completion $15M Placement
Later from Tetratherix
- Notification regarding unquoted securities - TTX
- Tegenix FDA Review Progress
- Notice of Annual General Meeting/Proxy Form
- Notification of cessation of securities - TTX
- TegenEOS Biologic Pathway
Follow Tetratherix into a list and get an email when it puts out news.
Follow Tetratherix